Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Friday 11 December, 2009

Summit Corporation

Wellcome Trust Grant

RNS Number : 9952D
Summit Corporation PLC
11 December 2009

Summit Corporation plc

("Summit" or "the Company")


  • Funding to develop Summit's C. difficile infectious disease programme

Oxford, UK, 11 December 2009 - Summit Corporation plc (AIM: SUMM) today announces that it has been awarded £2.2 million from the Wellcome Trust to fund the development of the Company's infectious disease programme targeting C. difficile, a bacteria that is posing a significant and growing healthcare threat. 

The award is made through the Wellcome Trust's Seeding Drug Discovery Initiative and provides over two years of funding to develop Summit's programme through until the end of preclinical development.  

Following today's award, Summit's C. difficile programme becomes part of the Company's expanded Partnered Product Portfolio that now comprises eight drug programmes. This portfolio requires no further investment from Summit but has contractual, success based regulatory and sales milestones worth over $160m plus sales royalties. In addition, Summit retains significant territory rights in some of the programmes, including C. difficile, which ensures the Company can benefit from future commercial agreements signed in these programmes.

Steven Lee, PhD, Chief Executive Officer of Summit said, "This £2.2 million award from The Wellcome Trust endorses Summit's scientific expertise in the area of infectious diseases.  Our C. difficile programme targets a significant and growing healthcare threat and the two years of funding will act as a potential value driver for the business as the programme is developed into a valuable commercial opportunity."  

About Clostridium difficile

The bacteria Clostridium difficile has emerged as a significant healthcare threat with approximately 50,000 cases per annum reported in the UK and an estimated 500,000 cases in the US.  Mortality rates in the UK due to C. difficile infection are four times higher than infections due to MRSA. In addition hyper-virulent strains are now endemic in Europe and the US, with these strains being associated with more severe disease and higher mortality rates. In the US, the cost of care for C. difficile is estimated at $1.1 billion per annum.  Therapy options remain limited with most common antibiotic treatments actually inducing C. difficile infection

Summit's early-stage programme has identified a novel class of small molecule compounds that have an attractive profile as a potential new therapy for the treatment of C. difficile. Early stage in vitro studies have shown the compounds inhibit the growth of C. difficile, but crucially, are highly selective for this bacterium. This is highly desirable property for any new treatment as it will help the normal, healthy balance of gut flora to re-establish whilst selectively killing the C. difficile bacteria.  In addition, the compounds display activity against the hyper-virulent strains 

Using the Wellcome Trust funding, the next stage of development is to establish proof of concept in the gold-standard in vivo model and also undertake studies to establish the mode of action for this novel set of compounds.  

-- ENDS -

For more information, please contact:

Steven Lee, PhD 
Richard Pye, PhD

Tel: +44 (0)1235 443939

Singer Capital markets
Shaun Dobson

Claes Sp

Tel: +44 (0)20 3205 7500

         About Summit plc

Summit plc is a UK based drug discovery company with a major focus on developing new therapeutics from its iminosugar drug discovery platform. 

Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drug candidates have had little success, and therefore offer a major opportunity for the discovery and development of new medicines.

Carbohydrates play critical roles in maintaining correct function of many normal processes in healthy individuals and provide a wealth of new targets for drug discovery. Iminosugars have the capability of accessing such targets and offer the potential of generating new medicines in a variety of major therapy areas.  Summit is currently focussed on metabolic diseases, including diabetes, and anti-virals.

Commercially, Summit has a track record of signing programme agreements and currently has an out-licensed product portfolio comprising of seven drug programmes with BioMarin, Orient Pharma, Evolva and the Lilly TB Drug Discovery Initiative. In the future these programmes may generate success based milestone payments and royalties for Summit. 

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at

About the Wellcome Trust

The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. 

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t